|

Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

RECRUITINGN/ASponsored by Albert Einstein College of Medicine
Actively Recruiting
PhaseN/A
SponsorAlbert Einstein College of Medicine
Started2022-06-27
Est. completion2026-06
Eligibility
Age18 Years – 64 Years
Healthy vol.Accepted
Locations2 sites

Summary

This project proposes to use telemedicine-delivered cognitive-behavioral therapy (CBT) enhanced with continuous glucose monitor (CGM) review to target diabetes distress in adults with type 1 diabetes. The efficacy of CBT for diabetes distress (CBT-DD) will be tested in comparison to commercial FDA-approved CGM only in a randomized controlled clinical trial. The investigators' central hypothesis is that the addition of a CBT intervention that targets diabetes distress and self-management directly will yield clinically significant improvements in both diabetes distress and glycemic control relative to CGM alone. The investigators propose to recruit 93 adults (age 18-64) with type 1 diabetes from a national population for an entirely virtual 6-month study over four years, with targeted recruitment of racial/ethnic minorities. In addition to standard measurement of HbA1c for glycemic control and validated patient-reported outcome (PRO) surveys, the investigators plan to innovatively integrate momentary psychological and behavioral data via smartphone-based ecological momentary assessment with CGM data to assess day-to-day changes in diabetes distress, affect, self-management, and glycemia over the course of the trial.

Eligibility

Age: 18 Years – 64 YearsHealthy volunteers accepted
Inclusion Criteria:

* Type 1 Diabetes (T1D) duration ≥6 months
* English or Spanish speaking
* At least moderate Diabetes Distress (DD) (score of ≥2 on T1D-Diabetes Distress Scale)
* Stable insulin treatment regimen (insulin prescription, use of pump, etc.) for at least 3 months prior to study enrollment

Exclusion Criteria:

* Comorbid psychiatric condition, including depression, anxiety, or suicidality, which may be independently associated with the main outcomes of DD or glycemic control. Comorbid psychiatric conditions listed above are being excluded because CBT-DD currently centers on mitigating specifically diabetes distress to improve glycemic outcomes
* In treatment for a psychological condition within the last 6 months or on a non-stable dose of psychiatric medication over the last 2 months
* Developmental or sensory disability interfering with participation
* Current pregnancy, as self-management and glycemic goals differ
* Participation in another behavioral intervention study
* Use of non-insulin medications or recent medical procedures that would impact glycemic control or use of CGM over the study
* Minors
* Subjects who do have the capacity to consent

Conditions2

DiabetesType 1 Diabetes

Locations2 sites

Yeshiva University
New York, New York, 10033
Jeffrey Gonzalez, PhD646-592-4376jeffrey.gonzalez@yu.edu
Albert Einstein College of Medicine
The Bronx, New York, 10461
Keyla Ordonez, BS631-747-9325keyla.ordonez@einsteinmed.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.